Sat.Aug 05, 2023 - Fri.Aug 11, 2023

article thumbnail

Pfizer faces whistleblower lawsuit from former compliance manager who says he flagged possible fraud in China

Fierce Pharma

After Pfizer allegedly fired a compliance manager for raising the flag on potential fraud activity in China, the former employee is hitting back. | Frank Han, Pfizer's former director of global compliance analytics, has filed a civil complaint against the drugmaker. Han claims he was terminated for identifying potential issues relating to the Foreign Corrupt Practices Act.

article thumbnail

Episode 1: The Role of ChatGPT in Strategic Account Management

Clarity Engagement Solutions

August 10, 2023 Episode 1: The Role of ChatGPT in Strategic Account Management Adipiscing elit dapibus, vulpu tate in donec tempor ultricies venenatis erat, aliquam posuere urna habitant rutrum euismod maecenas varius tortor nibh, sit amet tempor nibh finibus et. Episode 201: Leveling Up Your Career with Jane Chapman [link] Nulla porttitor accumsan tincidunt.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Bridging the Divide: Medical's Omnichannel Momentum

PharmExec

How pharma medical affairs and commercial teams are synchronizing their capabilities to boost omnichannel marketing strategies and better understand customer engagement needs.

Medical 98
article thumbnail

Real Chemistry and WhizAI Announce Partnership to Develop a Generative AI-Based Patient Journey Visualization and Analytics Solution

PM360

Real Chemistry , a leading provider of AI-driven insights and marketing and communications for the healthcare industry, is partnering with WhizAI , a generative AI-powered analytics platform purpose-built for life sciences and healthcare, to develop a patient journey visualization and analytics solution. This new platform promises to make it easier for clients to access accurate, contextual insights by asking conversational questions while also having the ability to visualize the process patient

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Eco-minded AstraZeneca doubles down on renewable energy push in Sweden

Fierce Pharma

AstraZeneca is often at the forefront when it comes to sustainability efforts among pharma companies. Now, the British drugmaker is doubling down on its clean energy commitments in Sweden.

Pharma 246
article thumbnail

Multiple myeloma bispecific antibody granted accelerated approval

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has granted accelerated approval of TALVEY (talquetamab-tgvs) to treat multiple myeloma. Janssen Pharmaceutical Companies of Johnson & Johnson’s first-in-class bispecific T-cell engaging antibody showed an overall response rate (ORR) of over 70 percent in heavily pre-treated multiple myeloma. Based on this data, TALVEY is indicated for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, includin

More Trending

article thumbnail

Doubling Down on Drug Adherence

Pharmaceutical Commerce

Creating a user-centric approach that harnesses both digital tools and behavioral science is key to getting—and maintaining—patients on therapy, and improving clinical, financial, and, ultimately, brand-success outcomes for pharma manufacturers.

article thumbnail

Supreme Court blocks Purdue Pharma's bankruptcy settlement, threatening immunity to Sackler family

Fierce Pharma

It’s been a rough summer for pharmaceutical companies trying to resolve lawsuits by declaring bankruptcy. | The Supreme Court has halted Purdue Pharma’s $6-billion bankruptcy settlement, which granted the company’s former owners—the Sackler family—immunity from civil suits related to the opioid crisis.

Pharma 240
article thumbnail

Solutions to Optimize Cell Therapy Development and Manufacturing

PharmaTech

Catalent's Martin De Brauwere and Maria Lopez react to cell therapy innovations and highlight strategies to optimize the drug development and manufacturing process with assistance from a CDMO.

article thumbnail

Q&A: Dr. Daniel Hernandez, Director of Medical Affairs and Hispanic Outreach, Global Healthy Living Foundation

PharmExec

Hernandez details how the non-profit organization advocates for improved access to care at the community, state, and federal levels, and amplifies education and awareness efforts within its social media communities.

Media 98
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Artificial Intelligence related patent filings increased in the pharmaceutical industry in Q2 2023

Pharmaceutical Technology

The global pharmaceutical industry experienced a 52% decline in the number of artificial intelligence related patent applications in Q2 2023 compared with the previous quarter, according to GlobalData's Patent Analytics.

article thumbnail

Astellas wins FDA approval of eye disease drug Izervay and may have edge in market battle with Apellis

Fierce Pharma

Less than four months after Astellas’ $5.9 billion buyout of eye disease specialist Iveric Bio, the deal is already making the Tokyo-based company look visionary. | Less than four months after Astellas’ $5.9 billion buyout of Iveric Bio, the FDA has signed off on the main asset acquired in the deal, the geographic atrophy treatment Izervay.

FDA 236
article thumbnail

Semaglutide demonstrates cardiovascular benefit

European Pharmaceutical Review

Headline results from Novo Nordisk’s “landmark” SELECT trial in cardiovascular outcomes has demonstrated a 20 percent reduction in major adverse cardiovascular events (MACEs) for semaglutide 2.4mg (Wegovy ® ) compared to a placebo. “People living with obesity have an increased risk of cardiovascular disease but to date, there are no approved weight management medications proven to deliver effective weight management while also reducing the risk of heart attack, stroke or cardio

article thumbnail

AI and Drug 'Re-Innovation'

PharmExec

The application of artificial intelligence is steadily finding a home in the pharma industry, but these tools may have unprecedented potential in a more nascent niche along the life sciences continuum: drug development.

Pharma 98
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Emergency Dialysis: A Crutch for Fee-For-Service Healthcare

MedCity News

Physicians often diagnose patients with chronic kidney disease (CKD) too late in the process, when dialysis is the only option left. This isn’t negligence on the part of physicians — it’s simply a consequence of a fee-for-service (FFS) healthcare model that works against patients’ financial well-being and deemphasizes preventative care.

article thumbnail

Amylyx's ALS drug Relyvrio gets off the ground as company eyes new brain disorder

Fierce Pharma

Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis (ALS) drug Relyvrio continues to wow Wall Street. | Amylyx’s amyotrophic lateral sclerosis drug Relyvrio ​​​​​​​continues to wow Wall Street. The drug brought in $98.2 million revenue in the second quarter, handily beating analysts’ consensus estimates of below $92 million.

article thumbnail

In the era of blockbuster obesity drugs, a personalized approach could boost outcomes

PharmaVoice

Ozempic and Wegovy have become household names for weight loss. But obesity is complex, and Phenomix Sciences is looking to bring a personalized medicine approach to the field.

article thumbnail

Embracing Programmatic Advertising to Enhance Targeting of HCPs

PharmExec

The precision of programmatic advertising is reshaping the way life sciences brands engage with healthcare professionals, offering enhanced personalization, scale, and optimization in today's digital landscape.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Hospitals Still Struggling to Get Back Online 4 Days After Cyberattack on Prospect Medical Holdings

MedCity News

Hospitals and outpatient treatment centers in at least three states are struggling to get their systems back online following a ransomware attack waged last week against parent company Prospect Medical Holdings. Some of these facilities have partially or completely halted patient care.

article thumbnail

Novo Nordisk posts 'best-case scenario' cardio outcomes data for star obesity drug Wegovy

Fierce Pharma

Novo Nordisk has been riding the momentum of weight loss drug Wegovy ever since it stormed onto the market in 2021, creating widespread hype and even some supply shortfalls. | In a large phase 3 trial, Wegovy cut the risk of major adverse cardiovascular events by 20% compared with placebo and standard of care, Novo said Tuesday. Specifically, investigators measured Wegovy's 2.4-mg dose for its ability to cut the risk of a cardio death, heart attack or stroke.

Marketing 232
article thumbnail

Artificial Intelligence related patent filings increased in the pharmaceutical industry in Q2 2023

Pharmaceutical Technology

The global pharmaceutical industry experienced a 52% decline in the number of artificial intelligence related patent applications in Q2 2023 compared with the previous quarter, according to GlobalData's Patent Analytics.

article thumbnail

DE&I Accountability in Pharma

PharmExec

Rebekah Martin, senior VP of reward, inclusion, and talent acquisition at AstraZeneca, discusses ways companies can remain accountable for DE&I efforts in pharma in this Pharmaceutical Executive Podcast video.

Pharma 98
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Babylon Shuts Down US Operations After Rescue Merger Falls Apart

MedCity News

This week, virtual care company Babylon Health permanently closed its U.S. operations and laid off 94 employees. The news came after the company’s rescue merger fell apart — Babylon had planned to go private through a deal with Swiss digital therapeutics firm MindMaze and Babylon creditor AlbaCore Capital.

96
article thumbnail

With sales in free fall, Bayer's new CEO Anderson considers structural change

Fierce Pharma

It took Bayer’s new CEO Bill Anderson about 20 seconds into his first quarterly conference call to go against the grain. | In his first quarterly earnings call since taking over as CEO at Bayer, Bill Anderson faced several questions about the structure of the company. He said to stay tuned until early 2024. The company reported a 14% decline in revenue for the quarter, with all three business sectors seeing a drop in sales.

Sales 232
article thumbnail

Case Study: Reducing the Environmental Impact of Pharmaceutical Advisory Boards

Impetus Digital

The Problem With in-person meetings resuming after the end of COVID-19-related restrictions, many of our clients have been eager to get back to these meetings, thinking that’s what their Key Opinion Leaders (KOLs) want. Traditionally, external pharmaceutical meetings such as national advisory boards are held at upscale hotels in large cities, no more than once or twice a year.

article thumbnail

What pharma companies are getting wrong about drug repositioning

PharmaVoice

Children’s Tumor Foundation president Annette Bakker is working to teach the industry the crucial difference between drug repurposing and drug repositioning.

Pharma 98
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Personalized Nutrition: Tomorrow’s Approach to Nutrition

MedCity News

In the future, research in personalized nutrition needs to focus on understanding the role of nutrition throughout the entire lifespan and address diet-related conditions through comprehensive interventions that go beyond simply choosing healthy foods.

Food 96
article thumbnail

'Like a dairy farm treats cows': Henrietta Lacks' estate hits Ultragenyx with gene therapy vector lawsuit

Fierce Pharma

Less than a month after the family of Henrietta Lacks reached a settlement with Thermo Fisher over its use of Lacks’ cells, another drugmaker stands accused of profiting from a racist medical syste | Less than a month after the family of Henrietta Lacks reached a settlement with Thermo Fisher over its use of Lacks’ cells, another drugmaker stands accused of profiting from a racist medical system.

Medical 228
article thumbnail

Pharma's ESG Equation: Materiality and Strategy are Key

PharmExec

Life sciences executives who are confronted by too many choices in launching their environmental, social, and governance programs can leverage these two foundational tools to hone in on the set of issues, actions, and disclosures they should prioritize to create value.

article thumbnail

ADC oncology therapy market to value over $36b by 2029

European Pharmaceutical Review

According to research from GlobalData, the pharmaceutical industry is shifting towards development of antibody-drug conjugates (ADC) as oncology treatments. The data showed that Daiichi Sankyo , Seagen and Roche are currently three of the most important companies in the ADC market. Daiichi Sankyo was predicted to remain the dominant player in this market.

article thumbnail

ABM Evolution: How Top Marketers Are Using Account-Based Strategies

In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.